The study will enroll 320 adults, comparing the efficacy of ontunisertib against a placebo. Clinical success will be measured at 24 weeks by the ability of a scope to pass through previously narrowed sections of the intestine, providing a clear visual indicator of reduced blockage. Researchers plan to monitor participants for a full 52 weeks to evaluate long-term durability and safety.

Agomab has already received clearance from a central ethics board in the U.S. and secured approval from Health Canada. With regulatory applications pending across Europe and Asia, the company expects to administer the first dose to a patient in the second half of this year. This trial represents a high-stakes effort to offer a non-surgical alternative for patients currently facing the high probability of invasive intestinal procedures.